Deep sequencing of circulating tumour DNA as a biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma

Progression-free survival following transarterial chemoembolisation (TACE) for hepatocellular cancer (HCC) is variable. We explored targeted sequencing of circulating tumour DNA (ctDNA) as a prognostic biomarker. Plasma samples (n=23) were collected at baseline and following TACE. Targeted, ultra-deep sequencing was conducted on 18 somatic mutations related to the molecular pathogenesis of HCC.